DYAI Earnings

Dyadic Reports Second Quarter 2025 Financial Results and Highlights of Recent Company Progress

Published August 13, 2025 at 08:01 PM

JUPITER, Fla., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for non-therapeutic applications in life sciences, food and nutrition, and industrial biotechnology utilizing its proprietary gene expression platforms, today announced its financial results for the second quarter of 2025, highlighting recent company progress.

Related Questions

How did the company's revenue and profit margins change year‑over‑year and quarter‑over‑quarter? What guidance did Dyadic provide for Q3 2025 and full‑year 2025, and how does it compare to analyst expectations? Did the company report any changes to its cash balance, cash burn rate, or liquidity position? Are there any upcoming financing events (e.g., equity offerings, debt issuances) that could dilute shareholders? Did the company disclose any updates to its proprietary gene expression platforms that could affect its competitive positioning? What analyst coverage or rating changes have occurred following the release, and what are the consensus price targets? What are the key risk factors highlighted in the earnings release (e.g., regulatory, IP, supply chain) that could affect future performance? How did the market react to the earnings announcement (stock price movement, volume) and what is the sentiment among institutional investors? What were Dyadic's actual Q2 2025 revenue, earnings per share, and cash flow figures, and how do they compare to consensus estimates? What new contracts, partnerships, or product milestones were announced, and how are they expected to impact revenue growth? How do Dyadic’s recent financial results and guidance compare to key competitors such as Ginkgo Bioworks, Zymergen, and other biotech firms focused on functional proteins? What is the current valuation (e.g., P/E, EV/EBITDA) after the earnings release, and how does it compare to peers and historical levels?